Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Aspirin CVD Indication On OTC Labeling Urged By FDA’s Jenkins

This article was originally published in The Tan Sheet

Executive Summary

A cardiovascular disease prevention indication on OTC aspirin could be on the horizon, particularly if industry heeds FDA's invitation to propose such a change to the internal analgesics monograph
Advertisement

Related Content

Drug Manufacturer Interest In Rx-To-OTC Pipeline Growing – FDA’s Ganley
Drug Manufacturer Interest In Rx-To-OTC Pipeline Growing – FDA’s Ganley
Drug Manufacturer Interest In Rx-To-OTC Pipeline Growing – FDA’s Ganley
Acetaminophen, NSAID Dose-Response Link To Hypertension Found In Study
Low-Dose Aspirin Safety, CVD Efficacy “Superior” To Higher Doses – McNeil
Low-Dose Aspirin Safety, CVD Efficacy “Superior” To Higher Doses – McNeil
Aspirin, NSAID GI Bleeding Language Could Replace Alcohol Warning
Bayer, McNeil St. Joseph Aspirin Ad Dispute Moves To Federal Court
Aspirin Professional Indications Add Use During Acute MI In FDA Final Rule
Aspirin Professional Indications Add Use During Acute MI In FDA Final Rule

Topics

Advertisement
UsernamePublicRestriction

Register

PS094574

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel